Morgan Stanley Examines HCA Holdings' Initial FY14 Guidance

In a report published Wednesday, Morgan Stanley analyst Andrew Schenker reiterated an Overweight rating and $55.00 price target on HCA (NYSE: HCA).

In the report, Morgan Stanley noted, “HCA issued initial FY14 guidance including reform benefit. While the high end of guidance came in above consensus, it is below our estimate of $6.94B. Upside in our model is primarily based on a higher reform benefit of 4% of adj. EBITDA vs. guidance of 1% to 2%.”

HCA Holdings closed on Tuesday at $48.52.